Takeda's Next Head May Owe Job To Failed Shionogi Merger Attempt
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's next president and CEO, the first from outside Japan, apparently owes his near future to the failure of a near merger with Shionogi last year.
Takeda Pharmaceutical's next president and CEO, the first from outside Japan, apparently owes his near future to the failure of a near merger with Shionogi last year. Takeda President Yasuchika Hasegawa and his Shionogi counterpart, Isao Teshirogi, had reached a merger agreement, but it was virtually vetoed by Shionogi's board chairman, company family namesake Motozo Shiono, who insisted in part the company name remain intact. The naming of Christophe Weber, formerly with GlaxoSmithKline PLC, to succeed Hasegawa was announced not long after. (Click here for more
)
"Failed Merger Prompted Takeda's Choice Of Frenchman As President" - Nikkei (Japan) (1/22/2014)